Investigational Drug Details
| Drug ID: | D055 |
| Drug Name: | Calcium |
| Synonyms: | Calcium, elemental; Elemental calcium |
| Type: | Chemical drug |
| DrugBank ID: | DB01373 |
| DrugBank Description: | Calcium plays a vital role in the anatomy, physiology and biochemistry of organisms and of the cell, particularly in signal transduction pathways. The skeleton acts as a major mineral storage site for the element and releases Ca2+ ions into the bloodstream under controlled conditions. Circulating calcium is either in the free, ionized form or bound to blood proteins such as serum albumin. Although calcium flow to and from the bone is neutral, about 5 mmol is turned over a day. Bone serves as an important storage point for calcium, as it contains 99% of the total body calcium. Low calcium intake may also be a risk factor in the development of osteoporosis. The best-absorbed form of calcium from a pill is a calcium salt like carbonate or phosphate. Calcium gluconate and calcium lactate are absorbed well by pregnant women. Seniors absorb calcium lactate, gluconate and citrate better unless they take their calcium supplement with a full breakfast. |
| PubChem ID: | 5460341 |
| CasNo: | 7440-70-2 |
| Repositioning for NAFLD: | No |
| SMILES: | [Ca] |
| Structure: |
|
| InChiKey: | OYPRJOBELJOOCE-UHFFFAOYSA-N |
| Molecular Weight: | 42.094 |
| DrugBank Targets: | Voltage-dependent L-type calcium channel subunit alpha-1C ligand; Calcium-transporting ATPase type 2C member 1 agonist; Troponin C, skeletal muscle agonist; Troponin C, slow skeletal and cardiac muscles agonist; Spectrin beta chain, non-erythrocytic 1 ago |
| DrugBank MoA: | Calcium plays a vital role in the anatomy, physiology and biochemistry of organisms and of the cell, particularly in signal transduction pathways. More than 500 human proteins are known to bind or transport calcium. The skeleton acts as a major mineral storage site for the element and releases Ca2+ ions into the bloodstream under controlled conditions. Circulating calcium is either in the free, ionized form or bound to blood proteins such as serum albumin. Parathyroid hormone (secreted from the parathyroid gland) regulates the resorption of Ca2+ from bone. Calcitonin stimulates incorporation of calcium in bone, although this process is largely independent of calcitonin. Although calcium flow to and from the bone is neutral, about 5 mmol is turned over a day. Bone serves as an important storage point for calcium, as it contains 99% of the total body calcium. Low calcium intake may also be a risk factor in the development of osteoporosis. The best-absorbed form of calcium from a pill is a calcium salt like carbonate or phosphate. Calcium gluconate and calcium lactate are absorbed well by pregnant women. Seniors absorb calcium lactate, gluconate and citrate better unless they take their calcium supplement with a full breakfast. The currently recommended calcium intake is 1,500 milligrams per day for women not taking estrogen and 800 milligrams per day for women on estrogen. There is close to 300 milligrams of calcium in one cup of fluid milk. Calcium carbonate is currently the best and least expensive form of calcium supplement available. |
| DrugBank Pharmacology: | Calcium (Ca2+) plays a pivotal role in the physiology and biochemistry of organisms and the cell. It plays an important role in signal transduction pathways, where it acts as a second messenger, in neurotransmitter release from neurons, contraction of all muscle cell types, and fertilization. Many enzymes require calcium ions as a cofactor, those of the blood-clotting cascade being notable examples. Extracellular calcium is also important for maintaining the potential difference across excitable cell membranes, as well as proper bone formation. |
| DrugBank Indication: | Calcium plays a vital role in the anatomy, physiology and biochemistry of organisms and of the cell, particularly in signal transduction pathways. It is vital in cell signaling, muscular contractions, bone health, and signalling cascades. |
| Targets: | CAST; COMP; CP; BMP4; MGP |
| Therapeutic Category: | -- |
| Clinical Trial Progress: | Phase 3 on-going (IRCT201408312709N29) |
| Latest Progress: | Under clinical trials |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted | |
|---|---|---|---|---|---|---|---|
| L0129 | NCT01265498 | Phase 2 | Completed | Has Results | March 2011 | April 6, 2018 | Details |
| L0228 | NCT02970942 | Phase 2 | Completed | Has Results | November 30, 2016 | November 16, 2021 | Details |
| L0530 | IRCT2014110511763N18 | Not applicable | Not Recruiting | No Results Available | 18/01/2015 | 22 February 2018 | Details |
| L0534 | JPRN-UMIN000003055 | Phase 2 | Not Recruiting | No Results Available | 18/01/2010 | 2 April 2019 | Details |
| L0622 | IRCT201408312709N29 | Phase 3 | Not Recruiting | No Results Available | 11/10/2014 | 22 February 2018 | Details |
| L0712 | IRCT20190819044565N2 | Phase 3 | Recruiting | No Results Available | 24/12/2019 | 13 January 2020 | Details |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Article ID | PMID | Source | Title | |
|---|---|---|---|---|
| A00343 | 35127371 | Acta Pharm Sin B | Therapeutic regulation of autophagy in hepatic metabolism. | Details |
| A00348 | 35126113 | Front Pharmacol | Fenofibrate Improves Insulin Resistance and Hepatic Steatosis and Regulates the Let-7/SERCA2b Axis in High-Fat Diet-Induced Non-Alcoholic Fatty Liver Disease Mice. | Details |
| A00558 | 35047114 | World J Diabetes | Thioredoxin interacting protein, a key molecular switch between oxidative stress and sterile inflammation in cellular response. | Details |
| A00671 | 35008682 | Int J Mol Sci | Emerging Roles of Calcium Signaling in the Development of Non-Alcoholic Fatty Liver Disease. | Details |
| A00698 | 34998993 | Clin Gastroenterol Hepatol | Association of Physical Activity With Risk of Liver Fibrosis, Sarcopenia, and Cardiovascular Disease in Nonalcoholic Fatty Liver Disease. | Details |
| A00806 | 34959760 | Nutrients | Blood Levels of the SMOC1 Hepatokine Are Not Causally Linked with Type 2 Diabetes: A Bidirectional Mendelian Randomization Study. | Details |
| A00824 | 34956386 | Evid Based Complement Alternat Med | Procyanidin B2 Alleviates Palmitic Acid-Induced Injury in HepG2 Cells via Endoplasmic Reticulum Stress Pathway. | Details |
| A01126 | 34862596 | Br J Pharmacol | Ruthenium 360 and mitoxantrone inhibit mitochondrial calcium uniporter channel to prevent liver steatosis induced by high-fat diet. | Details |
| A01259 | 34811857 | Aging Cell | Cisd2 slows down liver aging and attenuates age-related metabolic dysfunction in male mice. | Details |
| A01280 | 34803681 | Front Pharmacol | The Effects of Vitamin D Supplementation on Anthropometric and Biochemical Indices in Patients With Non-alcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis. | Details |
| A01307 | 34794237 | Biomed Pharmacother | Anti-inflammatory and anti-fibrotic effects of modafinil in nonalcoholic liver disease. | Details |
| A01484 | 34729306 | Acta Pharm Sin B | 3D disorganization and rearrangement of genome provide insights into pathogenesis of NAFLD by integrated Hi-C, Nanopore, and RNA sequencing. | Details |
| A01505 | 34718898 | Egypt Heart J | The associations between coronary artery disease, and non-alcoholic fatty liver disease by computed tomography. | Details |
| A01519 | 34710938 | Z Gastroenterol | Non-alcoholic fatty liver disease (NAFLD) is associated with an increased incidence of osteoporosis and bone fractures. | Details |
| A01546 | 34699301 | Adipocyte | Verapamil induces autophagy to improve liver regeneration in non-alcoholic fatty liver mice. | Details |
| A01578 | 34686753 | Sci Rep | Clinically silent LINE 1 insertion in the PNPLA3 gene may impede genotyping of the p.I148M variant. | Details |
| A01585 | 34684653 | Nutrients | Coffeeberry Activates the CaMKII/CREB/BDNF Pathway, Normalizes Autophagy and Apoptosis Signaling in Nonalcoholic Fatty Liver Rodent Model. | Details |
| A01696 | 34651580 | J Clin Invest | Sparcl1 promotes nonalcoholic steatohepatitis progression in mice through upregulation of CCL2. | Details |
| A01697 | 34651578 | J Clin Invest | Targeting adipose tissue to tackle NASH: SPARCL1 as an emerging player. | Details |
| A01863 | 34584580 | Prz Gastroenterol | Association of non-alcoholic fatty liver disease with coronary artery calcification progression: a systematic review and meta-analysis. | Details |